Literature DB >> 25828893

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Nidal Muvarak1, Shannon Kelley2, Carine Robert1, Maria R Baer3, Danilo Perrotti4, Carlo Gambacorti-Passerini5, Curt Civin2, Kara Scheibner2, Feyruz V Rassool6.   

Abstract

UNLABELLED: Leukemias expressing the constitutively activated tyrosine kinases (TK) BCR-ABL1 and FLT3/ITD activate signaling pathways that increase genomic instability through generation of reactive oxygen species (ROS), DNA double-strand breaks (DSB), and error-prone repair. The nonhomologous end-joining (NHEJ) pathway is a major pathway for DSB repair and is highly aberrant in TK-activated leukemias; an alternative form of NHEJ (ALT-NHEJ) predominates, evidenced by increased expression of DNA ligase IIIα (LIG3) and PARP1, increased frequency of large genomic deletions, and repair using DNA sequence microhomologies. This study, for the first time, demonstrates that the TK target c-MYC plays a role in transcriptional activation and subsequent expression of LIG3 and PARP1 and contributes to the increased error-prone repair observed in TK-activated leukemias. c-MYC negatively regulates microRNAs miR-150 and miR-22, which demonstrate an inverse correlation with LIG3 and PARP1 expression in primary and cultured leukemia cells and chronic myelogenous leukemia human patient samples. Notably, inhibition of c-MYC and overexpression of miR-150 and -22 decreases ALT-NHEJ activity. Thus, BCR-ABL1 or FLT3/ITD induces c-MYC expression, leading to genomic instability via augmented expression of ALT-NHEJ repair factors that generate repair errors. IMPLICATIONS: In the context of TK-activated leukemias, c-MYC contributes to aberrant DNA repair through downstream targets LIG3 and PARP1, which represent viable and attractive therapeutic targets. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25828893      PMCID: PMC4398615          DOI: 10.1158/1541-7786.MCR-14-0422

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  46 in total

1.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

2.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

3.  Targeted cancer therapeutics: biosynthetic and energetic pathways characterized by metabolomics and the interplay with key cancer regulatory factors.

Authors:  Ngoc-Ha T Dang; Arvind K Singla; Emily M Mackay; Frank R Jirik; Aalim M Weljie
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.

Authors:  Jinshui Fan; Li Li; Donald Small; Feyruz Rassool
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

6.  Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.

Authors:  Xabier Agirre; Antonio Jiménez-Velasco; Edurne San José-Enériz; Leire Garate; Eva Bandrés; Lucia Cordeu; Oscar Aparicio; Borja Saez; Germán Navarro; Amaia Vilas-Zornoza; Ignacio Pérez-Roger; Jesús García-Foncillas; Antonio Torres; Anabel Heiniger; María José Calasanz; Puri Fortes; José Román-Gómez; Felipe Prósper
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

Review 7.  Mechanisms of oncogenic chromosomal translocations.

Authors:  Michael Byrne; Justin Wray; Brian Reinert; Yuehan Wu; Jac Nickoloff; Suk-Hee Lee; Robert Hromas; Elizabeth Williamson
Journal:  Ann N Y Acad Sci       Date:  2014-02-16       Impact factor: 5.691

8.  Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.

Authors:  Annahita Sallmyr; Alan E Tomkinson; Feyruz V Rassool
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

9.  miR-22 represses cancer progression by inducing cellular senescence.

Authors:  Dan Xu; Fumitaka Takeshita; Yumiko Hino; Saori Fukunaga; Yasusei Kudo; Aya Tamaki; Junko Matsunaga; Ryou-U Takahashi; Takashi Takata; Akira Shimamoto; Takahiro Ochiya; Hidetoshi Tahara
Journal:  J Cell Biol       Date:  2011-04-18       Impact factor: 10.539

Review 10.  MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune.

Authors:  Alessandro Fatica; Francesco Fazi
Journal:  Int J Mol Sci       Date:  2013-10-18       Impact factor: 5.923

View more
  30 in total

1.  There and Back Again: The Middle Earth of DNA Repair.

Authors:  Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2016-10       Impact factor: 5.852

Review 2.  Altered DNA ligase activity in human disease.

Authors:  Alan E Tomkinson; Tasmin Naila; Seema Khattri Bhandari
Journal:  Mutagenesis       Date:  2020-02-13       Impact factor: 3.000

3.  Association between miRNA-binding site polymorphisms in double-strand break repair genes and risk of recurrence in patients with squamous cell carcinomas of the non-oropharynx.

Authors:  Lijun Zhu; Erich M Sturgis; Zhongming Lu; Hua Zhang; Peng Wei; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

Review 4.  Repair of DNA double-strand breaks by mammalian alternative end-joining pathways.

Authors:  Annahita Sallmyr; Alan E Tomkinson
Journal:  J Biol Chem       Date:  2018-03-12       Impact factor: 5.157

Review 5.  Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.

Authors:  Anna J Dellomo; Maria R Baer; Feyruz V Rassool
Journal:  Cancer Lett       Date:  2019-04-04       Impact factor: 8.679

6.  Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.

Authors:  Aksinija A Kogan; Michael J Topper; Anna J Dellomo; Lora Stojanovic; Lena J McLaughlin; T Michael Creed; Christian L Eberly; Tami J Kingsbury; Maria R Baer; Michael D Kessler; Stephen B Baylin; Feyruz V Rassool
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-27       Impact factor: 12.779

7.  Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.

Authors:  Daniele Caracciolo; Giada Juli; Caterina Riillo; Adriana Coricello; Francesca Vasile; Sara Pollastri; Roberta Rocca; Francesca Scionti; Nicoletta Polerà; Katia Grillone; Mariamena Arbitrio; Nicoletta Staropoli; Basilio Caparello; Domenico Britti; Giovanni Loprete; Giosuè Costa; Maria Teresa Di Martino; Stefano Alcaro; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  J Transl Med       Date:  2022-10-22       Impact factor: 8.440

Review 8.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

9.  LIG1 syndrome mutations remodel a cooperative network of ligand binding interactions to compromise ligation efficiency.

Authors:  Thomas J Jurkiw; Percy P Tumbale; Matthew J Schellenberg; Charlotte Cunningham-Rundles; R Scott Williams; Patrick J O'Brien
Journal:  Nucleic Acids Res       Date:  2021-02-22       Impact factor: 16.971

Review 10.  Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer.

Authors:  Tianzhen Wang; Guangyu Wang; Dapeng Hao; Xi Liu; Dong Wang; Ning Ning; Xiaobo Li
Journal:  Mol Cancer       Date:  2015-06-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.